Risk-Reducing Surgeries for Hereditary Ovarian Cancer

  • STATUS
    Recruiting
  • End date
    Sep 1, 2023
  • participants needed
    600
  • sponsor
    Lei Li
Updated on 21 January 2021

Summary

Based on studies of "Inherited Susceptible Genes Among Epithelial Ovarian Cancer" (NCT03015376, clinicaltrials.gov) and "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer" (NCT03291106, clinicaltrials.gov), we provide risk-reducing surgeries of salpingo-oophorectomy with/without hysterectomy for healthy carriers with mutation genes of hereditary ovarian cancer, which is defined ovarian cancer with relevant pathogenic mutations.

Details
Condition Hysterectomy, Lynch Syndrome, Breast Cancer, Ovarian Cancer, Oophorectomy, Hereditary Neoplastic Syndrome, Hereditary Breast and Ovarian Cancer, Recurrent Ovarian Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Hereditary Cancer Syndromes, hysterectomies, ovariectomy
Treatment follow-up, salpingo-oophorectomy only by laparoscopy, salpingo-oophorectomy with hysterectomy by laparoscopy
Clinical Study IdentifierNCT03294343
SponsorLei Li
Last Modified on21 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Carriers with known and definite mutation genes of hereditary ovarian cancer
With children and without further requirement of pregnancy
No less than 35 years for carriers with mutation gene of BRCA1
No less than 40 years for carriers with mutation gene of BRCA2
No less than 45 years for carriers with mutation genes of BRIP1, RAD51C, RAD51D and RAD51
No less than 50 years for carriers with mutation genes of ATM, MSH2, MLH1, SH6, PMS2, EPCAM and STK11

Exclusion Criteria

Without children
Not reaching appreciate ages
With contraindications of laparoscopy
Refusal of risk-reducing surgeries
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note